{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-242912","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.027475+00:00","generated_at":"2026-05-17T03:19:08.333389+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M","bullets":["Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.","No dose-limiting toxicities, treatment-related discontinuations, or Grade 4/5 adverse events observed across 55 treated patients.","14 of 16 Cohort 2 patients with SSTR2+ all tumors remain progression-free and on study (87.5%).","Preliminary cash, cash equivalents and short-term investments ~$174.1M as of Sep 30, 2025, funding operations into late 2026.","Initial efficacy data for additional 31 patients expected in 2026; company plans registration study based on emerging profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-242912","json":"https://secwatch.observer/filing/0001193125-25-242912.json","markdown":"https://secwatch.observer/filing/0001193125-25-242912.md","text":"https://secwatch.observer/filing/0001193125-25-242912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/0001193125-25-242912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/catx-20251020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:19:08.333389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}